[go: up one dir, main page]

AU2002354410A1 - Triazole compound and medicinal use thereof - Google Patents

Triazole compound and medicinal use thereof

Info

Publication number
AU2002354410A1
AU2002354410A1 AU2002354410A AU2002354410A AU2002354410A1 AU 2002354410 A1 AU2002354410 A1 AU 2002354410A1 AU 2002354410 A AU2002354410 A AU 2002354410A AU 2002354410 A AU2002354410 A AU 2002354410A AU 2002354410 A1 AU2002354410 A1 AU 2002354410A1
Authority
AU
Australia
Prior art keywords
triazole compound
medicinal use
medicinal
triazole
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002354410A
Inventor
Hiroshi Kawakami
Yuki Kitao
Akira Matsuo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Tobacco Inc
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of AU2002354410A1 publication Critical patent/AU2002354410A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12Oxygen or sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002354410A 2001-12-05 2002-12-04 Triazole compound and medicinal use thereof Abandoned AU2002354410A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001/371687 2001-12-05
JP2001371687 2001-12-05
PCT/JP2002/012735 WO2003048134A1 (en) 2001-12-05 2002-12-04 Triazole compound and medicinal use thereof

Publications (1)

Publication Number Publication Date
AU2002354410A1 true AU2002354410A1 (en) 2003-06-17

Family

ID=19180699

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002354410A Abandoned AU2002354410A1 (en) 2001-12-05 2002-12-04 Triazole compound and medicinal use thereof

Country Status (3)

Country Link
JP (1) JPWO2003048134A1 (en)
AU (1) AU2002354410A1 (en)
WO (1) WO2003048134A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2862060A1 (en) * 2003-11-06 2005-05-13 Galderma Res & Dev New diaryl sulfide derivatives, useful in pharmaceutical, dermatological or cosmetic compositions, prepared by solid phase synthesis
AR057455A1 (en) 2005-07-22 2007-12-05 Merck & Co Inc INHIBITORS OF HIV REVERSE TRANSCRIPTASE AND PHARMACEUTICAL COMPOSITION
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
KR20200111230A (en) 2008-12-31 2020-09-28 알데릭스, 인코포레이티드 Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CA2746832C (en) 2009-01-26 2017-10-03 Cytochroma Inc. Phosphate management with small molecules
BR112012015868A2 (en) 2009-12-11 2017-06-20 Autifony Therapeutics Ltd imidazolidinedione derivatives
BR112012025390B8 (en) 2010-04-28 2022-11-22 Astellas Pharma Inc TETRAHYDROBENZOTIOPHENE COMPOUND OR SALT THEREOF AND ITS USE IN THE TREATMENT OR PREVENTION OF HYPERPHOSPHATEMIA, AS WELL AS THE PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUND
EP2649066B1 (en) 2010-12-06 2015-10-21 Autifony Therapeutics Limited Hydantoin derivatives useful as kv3 inhibitors
JP6008953B2 (en) 2011-06-07 2016-10-19 アウトイフオンイ トヘラペウトイクス リミテッド Hydantoin derivatives as KV3 inhibitors
PL2772490T3 (en) 2011-10-27 2016-11-30 Aminoalkyl-substituted n-thienyl benzamide derivative
US9669030B2 (en) 2012-05-22 2017-06-06 Autifony Therapeutics Limited Hydantoin derivatives as Kv3 inhibitors
US9422252B2 (en) 2012-05-22 2016-08-23 Autifony Therapeutics Limited Triazoles as Kv3 inhibitors
BR112015003527A2 (en) 2012-08-21 2017-07-04 Ardelyx Inc compounds and methods for nhe-mediated antiport inhibition in the treatment of disorders associated with fluid retention or salt overload and disorders of the gastrointestinal tract.
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
RS58969B1 (en) 2013-04-12 2019-08-30 Ardelyx Inc Nhe3-binding compounds and methods for inhibiting phosphate transport
TWI594975B (en) * 2013-04-24 2017-08-11 第一三共股份有限公司 Dicarboxylic acid compound
CA3049679A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Inhibitors of nhe-mediated antiport
KR20240090875A (en) 2017-01-09 2024-06-21 알데릭스, 인코포레이티드 Compounds useful for treating gastrointestinal tract disorders
EP4523703A1 (en) * 2022-05-11 2025-03-19 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for treating or preventing cystic disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3769411A (en) * 1968-09-04 1973-10-30 Rohm & Haas Fungicidal 1,2,4-4h-triazole derivatives
FI73423C (en) * 1980-02-29 1987-10-09 Otsuka Pharma Co Ltd FRAMEWORK FOR THE FRAMEWORK OF PHARMACOLOGICAL VEHICLES TETRAZOLDERIVAT.
JPH0731386B2 (en) * 1986-09-19 1995-04-10 富士写真フイルム株式会社 Direct positive type silver halide photographic light-sensitive material
DE19728996A1 (en) * 1997-07-07 1999-01-14 Basf Ag Triazole compounds and their use

Also Published As

Publication number Publication date
JPWO2003048134A1 (en) 2005-04-14
WO2003048134A1 (en) 2003-06-12

Similar Documents

Publication Publication Date Title
AU2002349705A1 (en) Azole compound and medicinal use thereof
AU2002335536A1 (en) Pyrimidine compound and medicinal composition thereof
AU2001256184A1 (en) 6-aminoalkyl-dihydropyrimidines and the use thereof as medicaments against viraldiseases
WO2002089880A8 (en) Inhalers
AU2002258063A1 (en) Medicament applicator
AU2002365120A1 (en) Medicaments
AU2002354410A1 (en) Triazole compound and medicinal use thereof
AU2002253039A1 (en) Tramadol-based medicament
AU2002257562A1 (en) Deuterated 3-Piperidinopropiophenone and medicaments containing said compounds
AU2002315263A1 (en) Aluminium implant and use thereof
AU2002258221A1 (en) Medicinal composition
AU2001227084A1 (en) N-arylhydrazide compounds and use thereof as drugs
AU2002308889A1 (en) Novel heterocyclic compound and medicinal use thereof
AU1053501A (en) Polyazanaphthalene compound and medicinal use thereof
AU4432001A (en) Trityl-type compounds and their use
AUPR916301A0 (en) Pyrazolopyridine compound and pharmaceutical use thereof
AUPR606401A0 (en) Pyrazolopyridine compound and pharmaceutical use thereof
AUPR548601A0 (en) Pyrazolopyrazinecompound and pharmaceutical use thereof
AU2002354460A1 (en) Medicinal composition
AU2002251543A1 (en) Novel atisane compound and use thereof
AU2002215923A1 (en) Use of medicaments
AU2002323963A1 (en) Beta-ketoamide compounds and medicinal use thereof
AU2002349619A1 (en) Triazole derivative and medicinal composition containing the same
AU2002344600A1 (en) Indole compound and medicinal use thereof
AU2002237537A1 (en) Glycopyranosyloxypyrazole derivatives and medicinal use thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase